Coca-Cola (NYSE:KO) is not seeing the huge effect from GLP-1 usage that some investors feared when the drugs became more ...

Four clinical organizations jointly release an advisory with evidence-based nutrition and lifestyle interventions to enhance ...

Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

Although coverage restrictions remain in place, the trendiness of weight loss drugs may be creating a growing cost concern ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

IFF , a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is reshaping the sensory experience and ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. Eli Lilly (NYSE: LLY) has been a ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.